Table 1.
Patients’ characteristics before treatment.
| Variable | Modality | Placebo group | Timolol Group | p-value |
|---|---|---|---|---|
| n | 29 | 29 | — | |
| Age (years) | Mean (SD) | 56.5 (7.9) | 55.7 (10.8) | 0.76 |
|
Median (Min - Max) |
56.8 (41.8–77.5) |
53.5 (31.2–77.4) |
||
| Females (%) | n (%) | 17 (58.6) | 14 (48.3) | 0.43 |
| Nasal surgery | n (%) | 23 (79.3) | 22 (75.9) | 0.75 |
| Nasal septum perforation | n (%) | 7 (25.0) | 8 (27.6) | 0.82 |
| Nasal obstruction | n (%) | 23 (79.3) | 23 (79.3) | 1.00 |
| Blood transfusions in the last 3 months | n (%) | 5 (17.8) | 4 (13.8) | 1.00 |
| Hemoglobinemia | Mean ± SD | 117.62 (24.9) | 129.21 (22.7) | 0.09 |
| (g/L) |
Median (Min − Max) |
119 (79–160) |
134 (91–161) |
|
| Ferritinemia (µg/l) | Mean ± SD | 35.62 (39.1) | 42.76 (63.7) | 0.61 |
|
Median (Min − Max) |
23 (6–189) |
23 (7–350) |
||
| Systolic blood pressure (mmHg) |
Mean ± SD Median (Min − Max) |
128.2 (18.5) 130 (91–185) |
130.0 (12.5) 128 (109–159) |
0.68 |
| Diastolic blood pressure (mmHg) |
Mean ± SD Median (Min − Max) |
80.4 (12.1) 78 (61–116) |
78.7 (10.4) 77 (61–97) |
0.57 |
| Mutated gene | n (%) | 1.00 | ||
| ALK1 | 18 (62.1) | 19 (65.5) | ||
| ENG | 9 (31.0) | 9 (31.0) | ||
| SMAD4 | 1 (3.4) | 0 (0.0) | ||
| On going | 0 (0.0) | 1 (3.4) | ||
| Unknown | 1 (3.4) | 0 (0.0) |